Sanofi Genzyme, which specializes in rare diseases, said it will let go of 130 workers at its Allston Landing biomanufacturing facility in Boston.
News of the layoffs comes on the heels of Sanofi reporting strong fourth-quarter global growth of 16.8% for the unit “due to contributions from the new immunology franchise,” the company reported Wednesday. For the full year, Genzyme’s global sales were up 15.2% at $6.97 billion.
Overall, however, Sanofi reported a 29.5% fourth-quarter decline ($897 million) and 22.8% ($3.84 billion) slide for the year that some analysts partly attribute to a hit to sales of its diabetes drugs Lantus and Toujeo on CVS Health and UnitedHealthcare formulary exclusions.
Sanofi bought Genzyme in 2011 for more than $20 billion. Sanofi has about 5,000 employees in Massachusetts located at six sites in the state.
“We are currently implementing a change at our Allston Landing plant that will result in a reduction in headcount,” Sanofi spokeswoman Ashleigh Koss told Fierce in an e-mail. “This change is associated with the outsourcing of certain aspects of the production process and various improvements to technology and operations that have been implemented. As a result, we are reducing staffing levels to more closely align with the current level of activity at the site.”
Like others in the industry, Sanofi has adapted to tougher payer tactics by reshaping itself partly through M&A and layoffs. As part of those efforts, the company noted Wednesday of the possible sale of its European generics business. That sale could happen in the second half of 2018. Reports have pegged the unit value at around $2.4 billion with two drugmakers and several private equity companies the likely bidders.
By Joseph Keenan
Source: Fierce Pharma
Pharma and medical imaging company MedTrace announced the appointment of Nicholas Borys, M.D., as Chief Medical Officer (CMO). Dr. Borys is a skilled and experienced healthcare executive with over 25 years experience in advancing portfolios of novel therapies across diverse indications in cardiovascular, cancer, and central nervous system disease.
Eli Lilly and Company has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for its Limerick site. The move is aimed at boosting the company’s production of biologic active ingredients, including those for its approved Alzheimer’s treatment.
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.
